Serotonin Centers Announces Addition of NAD+ Therapy to Anti-Aging Medical Offerings
Serotonin Anti-Aging Centers (Serotonin), the nation's fastest-growing med spa franchise and a pioneer of medical advancements in anti-aging/longevity, announced today the addition of NAD+ Therapy. Now available at all U.S. franchise locations, this innovative therapy is offered via both IV infusion and an injectable shot to boost cellular regeneration and overall energy and health.
NAD+ (nicotinamide adenine dinucleotide) is a naturally occurring coenzyme essential to cellular metabolism and energy production. As the foundation of many biological processes, NAD+ plays a vital role in maintaining mitochondrial function, supporting cognitive clarity, and enhancing physical endurance. Recent advancements in the field of regenerative medicine have highlighted its potential not only to mitigate some of the visible signs of aging but also to optimize the body's natural repair mechanisms—a benefit eagerly embraced by the growing biohacking and wellness communities.
'Cells don't age in the traditional sense,' explained Dr. Lisa Golding Granado, MD, Chief Medical Officer of Serotonin Centers. 'Rather, they experience a slower turnover and retain a remarkable capacity to regenerate. With restorative therapies such as NAD+, we can enhance cell turnover and stimulate the body's innate healing processes, effectively restoring energy levels and overall vitality.' Dr. Granado's statement underscores the paradigm shift in understanding aging—not as a relentless deterioration, but as a modifiable process that can be influenced by targeted interventions.
The newly introduced NAD+ therapy is administered through two distinct methods: a slow drip IV infusion or a precise daily injectable shot five days per week. The slow drip IV technique allows for a sustained, controlled delivery of NAD+ into the bloodstream, ensuring optimal bioavailability and prolonged therapeutic benefits. Conversely, the injection option provides a quick and efficient method for clients seeking a more consistent boost in cellular energy and recovery. Both approaches are designed with client safety and comfort in mind, drawing upon extensive clinical expertise and a commitment to evidence-based practice.
For individuals seeking anti-aging benefits, NAD+ therapy offers an attractive option to support overall health and longevity. It has shown promise in enhancing athletic performance by accelerating recovery times, reducing inflammation, and increasing stamina. Moreover, the sought-after therapy is emerging as a favorite among biohackers who are keen to optimize mental clarity and maintain high levels of physical performance amidst the stresses of modern life.
'At Serotonin Centers, we are dedicated to providing our clients with the most advanced and scientifically supported treatments available,' Dr. Granado added. 'NAD+ therapy not only targets the visible signs of aging but also improves cellular metabolism and energy production, leading to enhanced performance and recovery for athletes, high-performing professionals, and everyday individuals alike.' This commitment to integrating cutting-edge regenerative medicine aligns with Serotonin Centers' mission to offer a comprehensive, concierge-style healthcare model that combines the expertise of medical practitioners with the personalized attention of health coaches, easily accessible to those who seek to optimize their health, and both increase and improve their lifespan.
The integration of NAD+ therapy into Serotonin Centers' suite of anti-aging solutions represents a milestone in the evolution of wellness services. By harnessing the restorative power of NAD+, the centers provide a proactive approach to aging—one that focuses on preserving and enhancing the body's natural capacity for repair and regeneration. This innovation not only reinforces Serotonin Centers' position as a leader in the longevity field but also offers a transformative pathway for individuals seeking to extend their healthspan and maintain peak physical and mental performance.
For more information on NAD+ therapy and other anti-aging treatments, please visit your nearest Serotonin Centers location or contact our media relations team.
ABOUT SEROTONIN ANTI-AGING CENTERS:
Aptly named after the hormone that stabilizes human feelings of well-being and overall happiness, Serotonin Centers provides members with the road map for maximizing wellness and optimizing healthspan. The anti-aging and longevity franchise intersects the expertise of both medical practitioners and health coaches in a concierge eco-system under one roof to slow down the human biological clock and extend the prime years of looking and feeling your best. Founded in 2021 by Eric and Kim Casaburi to fill a void in the med spa space, the franchise brand now has more than 90 locations in development and 12 locations open and operating in the U.S. Those interested in visiting or investing in a Serotonin Anti-Aging Center can find more information on www.serotonincenters.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Hydration Room Expands to Rancho Cucamonga with New Wellness Clinic Focused on Proactive, Personalized Care
RANCHO CUCAMONGA, Calif., June 13, 2025 /PRNewswire/ -- Hydration Room, a leader in medically guided IV therapy and proactive wellness treatments, proudly announces the opening of its newest clinic at Victoria Gardens in Rancho Cucamonga marking its first location in San Bernardino County. This opening marks the next step in Hydration Room's statewide expansion, with multiple Bay Area clinics launching later this summer. "Rancho Cucamonga is a vibrant, growing community — the perfect place for Hydration Room to bring its wellness-first philosophy," said Michelle Mendoza, CEO of Hydration Room. "We're thrilled to support new patients in feeling their best and building sustainable, healthy routines." Far more than a hangover cure, Hydration Room offers IV and injection therapies designed to support energy, immunity, sleep, mood, fitness recovery, skin health, stress relief, and more. It's a personalized, medical-grade approach to feeling your best starting from the cellular level up. The clinic will also offer Hydration Room's newly launched NAD+ Membership, a monthly program designed to support long-term energy, mental clarity, and cellular health through consistent NAD+ therapy. "We're excited to bring our wellness-first model to Rancho Cucamonga," said Dr. Brett Florie, board-certified anesthesiologist and Founder of Hydration Room. "Our goal is to help patients take control of their health with personalized treatment plans, whether they're focused on recovery, longevity, or preventing burnout." Each patient begins with a complimentary consultation from a licensed Nurse Practitioner, who guides patients through tailored treatment plans based on their lifestyle and wellness goals. Whether you're rehydrating after travel, recovering from stress or illness, or investing in long-term vitality, Hydration Room offers a full menu of supportive therapies. To celebrate, a Grand Opening Celebration will be held on Saturday, June 28, 2025, and is open to the community. Guests will enjoy: Free B-12 shots Light bites Exclusive event-only offers RSVP to save your spot with the medical team for a B-12 shot. Founding Memberships are available now for the first 100 members, offering VIP access and 20% off monthly pricing. New patients can also enjoy 50% off their first treatment with promo code TRY50. The new clinic joins over 35 locations across Southern California, many of which feature private treatment rooms and a calming, physician-designed setting. To learn more or become a Founding Member, visit About Hydration RoomFounded in 2014 by board-certified anesthesiologist Dr. Brett Florie, Hydration Room is redefining modern wellness with personalized, physician-designed IV and injection therapy. With over 30 clinics across Southern California, Hydration Room blends medical expertise with a high-touch patient experience to deliver fast, effective treatments that support energy, immunity, recovery, longevity, and overall wellness. From NAD+ therapy to custom treatment plans guided by licensed medical professionals, Hydration Room empowers patients to take control of their health—starting at the cellular level. Media ContactTina McClellandVP View original content to download multimedia: SOURCE Hydration Room Sign in to access your portfolio
Forbes
a day ago
- Forbes
The Triumphs And Trials Of Duchenne Gene Therapy
Today, the world stands at a crossroads in genetic medicine, as seen in Destiny's Child No Longer: Rewriting Genetic Fate on the topic. This story examines the progress and ongoing challenges in gene therapy for Duchenne muscular dystrophy, offering hope to families while underscoring the need for caution and continued research. Advances in gene therapy are beginning to change the narrative for children with genetic diseases like Duchenne muscular dystrophy. This rare disease has long meant progressive muscle weakness, loss of mobility, and shortened lives. For decades, families faced this diagnosis with limited options in the form of treatments that managed symptoms but did not alter the disease's inevitable trajectory. Duchenne muscular dystrophy primarily affects boys and begins in early childhood, usually between the ages of three and six. Children with this condition experience gradual muscle weakness, initially involving the hips and legs and later spreading to the shoulders and arms. Over time, the muscles deteriorate, making it difficult to walk, climb stairs, or lift objects. Most children lose the ability to walk during their teenage years. Eventually, vital muscles that support the heartbeat and breathing are affected, leading to severe complications. The root cause is a change in a single gene that prevents the body from making a crucial muscle protein. Without this protein, muscle cells are fragile and prone to rapid breakdown. Until recently, treatments could only slow the decline or help with symptoms, but they could not stop or reverse the disease. Gene therapy provides the body with the necessary instructions to produce a missing protein that is essential for muscle building. For Duchenne muscular dystrophy, this means helping muscle cells produce the proteins they need. Recent advances have made this possible, using tiny viral carriers to deliver the new gene. Providing treatment for the disease before significant muscle damage occurs is crucial. Clinical trials have shown promising outcomes. Some children who received gene therapy have regained muscle strength and improved their ability to walk. Although these milestones are preliminary, they are significant compared to traditional treatments and highlight the potential of genetic medicine. However, this progress has not come without risk. Earlier this year, Sarepta Therapeutics reported the first death linked to its gene therapy, Elevidys, used to treat Duchenne muscular dystrophy. The patient, a 16-year-old boy, died from acute liver failure following treatment. While liver injury is a known possible side effect of Elevidys and other gene therapies that use adeno-associated viruses as delivery vehicles, this was the first time a fatal case of acute liver failure had been observed among more than 800 patients treated in clinical trials or through commercial use. Further testing revealed that the patient had a recent cytomegalovirus infection, which can also damage the liver and may have contributed to the outcome. According to Sarepta, acute liver injury is highlighted in Elevidys' prescribing information, but the severity seen in this case had not previously been reported. This incident prompted renewed discussion about how to balance the urgent need for innovative treatments with the responsibility to ensure patient safety, especially as gene therapies become more widely used for treating rare diseases. The most extensive study to date of Elevidys, known as the EMBARK trial, provides a clearer picture of what this gene therapy can and cannot do for children with Duchenne muscular dystrophy. In this study, Elevidys did not meet its primary goal of showing a clear, measurable improvement in overall muscle function after one year compared to children who did not receive the therapy. However, there were encouraging signs: children who received Elevidys showed some improvements in specific activities, such as standing up from the floor and walking or running short distances. Tests also confirmed that the therapy helped their muscles produce the protein they are missing. The progress made in gene therapy for Duchenne muscular dystrophy is not just changing the outlook for this single disease. It is opening new doors for people living with many other inherited conditions. The scientific advances, regulatory lessons, and patient experiences from Duchenne gene therapy are informing how researchers and doctors approach similar treatments for other rare diseases. As more is learned about delivering genes safely and effectively, these breakthroughs could one day benefit a broader group of patients who currently have few or no treatment options. However, it is essential to remember that innovation must be accompanied by careful oversight and a steadfast commitment to safety. The complexities of gene delivery systems, immune responses to viral vectors, and the risk of off-target effects remain significant scientific hurdles that we must navigate with caution and responsibility. Real-world stories from families offer the most compelling evidence of gene therapy's potential. Some children who once faced a lifetime in a wheelchair have regained the ability to walk and play. These breakthroughs show how science can change lives. But progress is rarely smooth. Each step forward brings new questions and responsibilities. As we stand at the threshold of this new era, it is up to scientists, families, and society to work together, striking a balance between hope and caution, and innovation and safety. Only by learning from both our successes and setbacks can we build a future where a child's genetic fate is not predetermined.
Medscape
2 days ago
- Medscape
Migraine Expert Renews Call for Prompt, Effective Management
OTTAWA — Therapies that target calcitonin gene-related peptide (CGRP) should be used up front in the treatment and prevention of migraine because of their efficacy, safety, and potential to modify the disease course, an expert said. Speaking at the annual meeting of the Canadian Neurological Sciences Federation (CNSF) Congress 2025, David Dodick, MD, emeritus professor of neurology at Mayo Clinic in Phoenix, reiterated the appeal that was first published in an American Headache Society position statement: That migraine therapies that target CGRP become first-line treatments for migraine. A Bold Call Some of the available monoclonal antibodies to treat migraine include erenumab, fremanezumab, galcanezumab, and eptinezumab. The class of 'gepants' includes rimegepant and atogepant. All these treatments target CGRP. 'This was a type of expert consensus opinion,' Dodick told Medscape Medical News , referring to the 'rather bold' position statement. 'The real-world evidence supports what we saw in clinical trials, and we now know the safety profile of these [therapies] because we've had them for almost 8 years of use in clinical practice. They are not first-line [therapies] simply because of cost.' The largest prospective study on the use of anti-CGRP monoclonal antibodies demonstrated robust responses to these therapies. Because CGRP-targeting therapies are well tolerated, discontinuation due to adverse events is generally not a concern, and increased efficacy may be realized if patients stay the course with CGRP-targeting therapies, said Dodick. 'You can imagine that if people are able to tolerate them and stay on these drugs longer, then efficacy is cumulative over time. Adherence and compliance increase the response rate over time,' said Dodick. Early Treatment Vital 'It really does matter how early you get to the patient and treat them effectively, both from the standpoint of treating an individual episode of migraine and from the prevention standpoint: That is, treating the disease earlier,' said Dodick. 'The more frequent that migraines are, and the more you allow them to be frequent, the more likely they are to progress to a daily migraine, and the more difficult they are to manage.' In the US and Canada, patients with migraine must first fail other treatments before they are prescribed newer agents like CGRP monoclonal antibodies or gepants, and this requirement creates the potential for a lapse in care, noted Dodick. 'Patients can become discouraged and lost to follow-up if they fail one medicine and then two medicines,' which he said supports the case for first-line access to CGRP-targeting migraine therapies. High-Impact Agents The efficacy of migraine treatments that target CGRP is convincing, said Michael Hill, MD, professor of clinical neuroscience at the University of Calgary's Cumming School of Medicine, Calgary. 'For some patients, they can get back to living a relatively normal life,' said Hill, who also is CNSF president. 'It can be a remarkable evolution. They go from being nonfunctioning and not working to being fully functional again because their migraine is not chronic, or their recurrent migraines are not so disabling.' Seeing patients who are unable to access these therapies is disheartening, Hill told Medscape Medical News. 'It is hard to see them denied this therapy.' The preventive potential that these therapies could offer would certainly be welcome, Hill added. 'The idea that some of these people who start with simple migraine and progress to a chronic, refractory migraine state, and that these might actually be preventable with early treatment, is really exciting.' Episodic treatment of migraine has not altered the disease course. 'The focus on migraine therapy has been on acute treatment and not so much on this idea that you might prevent the evolving chronicity of the disease.'
